An Exploratory Maintenance Trial Evaluating the Effect of BI 655064 in Lupus Nephritis Patients Who Have Achieved a Meaningful Response Either at the End of 1293.10 or After an Induction Treatment Outside of 1293.10
Phase of Trial: Phase II
Latest Information Update: 22 Feb 2019
At a glance
- Drugs BI 655064 (Primary)
- Indications Lupus nephritis
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim
- 26 Jan 2018 Planned End Date changed from 17 Oct 2020 to 29 Jun 2022.
- 26 Jan 2018 Planned primary completion date changed from 16 Aug 2020 to 29 Mar 2022.
- 26 Jan 2018 Status changed from not yet recruiting to recruiting.